Brief: Helix BioPharma Completes Third Dosing Cohort and Initiates Enrollment of the Next Cohort in U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47
30/05/2018 22:13
May 30 (Reuters) - Helix Biopharma Corp HBP.TO :
* HELIX BIOPHARMA CORP. COMPLETES THIRD DOSING COHORT AND
INITIATES ENROLLMENT OF THE NEXT COHORT IN U.S. COMBINATION
TREATMENT STUDY OF ITS LUNG CANCER DRUG CANDIDATE L-DOS47
Source text for Eikon: ID:nGNX5VnL8n
Further company coverage: HBP.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020